These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12219556)

  • 21. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
    McBride D
    ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
    [No Abstract]   [Full Text] [Related]  

  • 22. Accelerated approval regulations may need overhaul, panel suggests.
    Finkelstein JB
    J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
    [No Abstract]   [Full Text] [Related]  

  • 23. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug approval triggers debate on future direction for cancer treatments.
    Frantz S
    Nat Rev Drug Discov; 2006 Feb; 5(2):91. PubMed ID: 16521324
    [No Abstract]   [Full Text] [Related]  

  • 25. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 26. Should the FDA be the doctor of last resort?
    DeVita VT
    Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
    [No Abstract]   [Full Text] [Related]  

  • 27. Swimming upstream: an advocate reflects on cancer research and social realities.
    Mayer M
    J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190
    [No Abstract]   [Full Text] [Related]  

  • 28. FDA approves new drug for specific type of advanced breast cancer.
    Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
    [No Abstract]   [Full Text] [Related]  

  • 29. The ODAC Chronicles: part 7. Tale of two goals.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):939-41. PubMed ID: 16336083
    [No Abstract]   [Full Text] [Related]  

  • 30. Oncology update.
    Smart M
    Oncol Nurs Forum; 2011 Jul; 38(4):485-6. PubMed ID: 21708539
    [No Abstract]   [Full Text] [Related]  

  • 31. Better prioritization may speed approval of adjuvant therapies in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment for advanced kidney cancer.
    FDA Consum; 2006; 40(2):3. PubMed ID: 16673450
    [No Abstract]   [Full Text] [Related]  

  • 33. Recombinant IL-11 approved as platelet booster.
    Nat Biotechnol; 1998 Jan; 16(1):7. PubMed ID: 9447578
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA approves extra safe chemotherapy drug.
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):618-9. PubMed ID: 12503201
    [No Abstract]   [Full Text] [Related]  

  • 35. Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin.
    Elias D; Pocard M; Sideris L; Edè C; Ducreux M; Boige V; Lasser P
    Br J Surg; 2004 Apr; 91(4):455-6. PubMed ID: 15048746
    [No Abstract]   [Full Text] [Related]  

  • 36. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323
    [No Abstract]   [Full Text] [Related]  

  • 37. An overview of the drug approval process.
    Martinez LJ
    Res Initiat Treat Action; 2002; 8(1):11-7. PubMed ID: 12489521
    [No Abstract]   [Full Text] [Related]  

  • 38. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

  • 39. The ODAC chronicles: part 1. My first ODAC experience.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):709-12. PubMed ID: 15485306
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV drugs. FDA new drug approval rate lowest in 10 years.
    AIDS Policy Law; 2007 Jan; 22(2):5. PubMed ID: 17323437
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.